212 related articles for article (PubMed ID: 27122057)
1. Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses.
Galant NJ; Bugyei-Twum A; Rakhit R; Walsh P; Sharpe S; Arslan PE; Westermark P; Higaki JN; Torres R; Tapia J; Chakrabartty A
Sci Rep; 2016 Apr; 6():25080. PubMed ID: 27122057
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.
Sekijima Y; Kelly JW; Ikeda S
Curr Pharm Des; 2008; 14(30):3219-30. PubMed ID: 19075702
[TBL] [Abstract][Full Text] [Related]
3. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
[TBL] [Abstract][Full Text] [Related]
4. Exploration of the Misfolding Mechanism of Transthyretin Monomer: Insights from Hybrid-Resolution Simulations and Markov State Model Analysis.
Zhou S; Cheng J; Yang T; Ma M; Zhang W; Yuan S; Lo GV; Dou Y
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31861226
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9629-34. PubMed ID: 22645360
[TBL] [Abstract][Full Text] [Related]
6. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.
Almeida MR; Gales L; Damas AM; Cardoso I; Saraiva MJ
Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):587-96. PubMed ID: 16266291
[TBL] [Abstract][Full Text] [Related]
7. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?
Palaninathan SK
Curr Med Chem; 2012; 19(15):2324-42. PubMed ID: 22471981
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
9. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
Green NS; Foss TR; Kelly JW
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14545-50. PubMed ID: 16195386
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum: Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses.
Galant NJ; Bugyei-Twum A; Rakhit R; Walsh P; Sharpe S; Arslan PE; Westermark P; Higaki JN; Torres R; Tapia J; Chakrabartty A
Sci Rep; 2016 Jun; 6():27679. PubMed ID: 27282221
[No Abstract] [Full Text] [Related]
11. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
Johnson SM; Wiseman RL; Sekijima Y; Green NS; Adamski-Werner SL; Kelly JW
Acc Chem Res; 2005 Dec; 38(12):911-21. PubMed ID: 16359163
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
13. Physiological IgM class catalytic antibodies selective for transthyretin amyloid.
Planque SA; Nishiyama Y; Hara M; Sonoda S; Murphy SK; Watanabe K; Mitsuda Y; Brown EL; Massey RJ; Primmer SR; O'Nuallain B; Paul S
J Biol Chem; 2014 May; 289(19):13243-58. PubMed ID: 24648510
[TBL] [Abstract][Full Text] [Related]
14. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
Sekijima Y; Dendle MA; Kelly JW
Amyloid; 2006 Dec; 13(4):236-49. PubMed ID: 17107884
[TBL] [Abstract][Full Text] [Related]
15. Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
Yokoyama T; Mizuguchi M
J Med Chem; 2019 Feb; 62(4):2076-2082. PubMed ID: 30688456
[TBL] [Abstract][Full Text] [Related]
16. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.
Miller SR; Sekijima Y; Kelly JW
Lab Invest; 2004 May; 84(5):545-52. PubMed ID: 14968122
[TBL] [Abstract][Full Text] [Related]
17. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.
Si JB; Kim B; Kim JH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922648
[TBL] [Abstract][Full Text] [Related]
18. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.
Klimtchuk ES; Prokaeva T; Frame NM; Abdullahi HA; Spencer B; Dasari S; Cui H; Berk JL; Kurtin PJ; Connors LH; Gursky O
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6428-E6436. PubMed ID: 29941560
[TBL] [Abstract][Full Text] [Related]
19. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.
Choi S; Reixach N; Connelly S; Johnson SM; Wilson IA; Kelly JW
J Am Chem Soc; 2010 Feb; 132(4):1359-70. PubMed ID: 20043671
[TBL] [Abstract][Full Text] [Related]
20. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.
Sekijima Y; Hammarström P; Matsumura M; Shimizu Y; Iwata M; Tokuda T; Ikeda S; Kelly JW
Lab Invest; 2003 Mar; 83(3):409-17. PubMed ID: 12649341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
